Related Experiment Video
Updated: Aug 10, 2025
10:15
Identification of the Source of Secreted Proteins in the Kidney by Brefeldin A Injection
Published on: November 10, 2021
1.9K
Antifibrotic Soluble Thy-1 Correlates with Renal Dysfunction in Chronic Kidney Disease
Anja Saalbach1, Ulf Anderegg1, Ralph Wendt2
1Department of Dermatology, Venereology and Allergology, University of Leipzig Medical Center, 04103 Leipzig, Germany.
International Journal of Molecular Sciences
|February 11, 2023
Summary
Soluble Thymocyte differentiation antigen-1 (sThy-1) levels rise with declining kidney function in chronic kidney disease (CKD). This biomarker may indicate kidney fibrosis and potentially act as an antifibrotic factor.
Area of Science:
- Nephrology
- Immunology
- Fibrosis Research
Background:
- Kidney fibrosis is a key driver of chronic kidney disease (CKD) progression and irreversible organ damage.
- Thymocyte differentiation antigen-1 (Thy-1) influences fibroblast activity in fibrosis and exists in soluble forms (sThy-1) in bodily fluids.
Purpose of the Study:
- To investigate the association between soluble Thy-1 (sThy-1) and clinical parameters in hemodialysis patients versus those with preserved renal function.
- To examine Thy-1 expression in kidney tissue in a mouse model of diabetic CKD.
Main Methods:
- Measured serum and urinary sThy-1 concentrations in CKD patients and controls.
- Assessed Thy-1 mRNA and protein expression in kidney tissue from diabetic CKD mice and controls.
- Analyzed the impact of pro-fibrotic mediators on Thy-1 expression and sThy-1 release from fibroblasts.
Main Results:
- Serum and urinary sThy-1 levels significantly correlated with reduced renal function, irrespective of diabetes.
- Serum creatinine was an independent inverse predictor of serum sThy-1, and sThy-1 predicted renal function markers.
- Diabetic CKD mice exhibited increased kidney Thy-1 expression and elevated urinary sThy-1.
Conclusions:
- sThy-1 levels reflect declining kidney function in CKD patients.
- Thy-1 expression is upregulated in the kidneys of mice with diabetic CKD.
- Thy-1 may play a role in controlling kidney fibrosis and could potentially serve as an antifibrotic factor.
Related Concept Videos
01:11Renal Failure: Dose Adjustments
128
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
128
01:22Heart Failure Drugs: Diuretics
440
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
440
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
480
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
480
01:24Chronic Kidney Disease II: Clinical Manifestations
57
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
57
01:17Factors Affecting Renal Clearance: Renal Impairment
131
Renal dysfunction significantly impairs the renal clearance of drugs, leading to potential complications in drug therapy. Renal failure, which can be caused by various factors, poses a significant challenge in the elimination of drugs from the body.
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
131
01:30Acute Kidney Injury IV: Diagnostic Studies and Prevention
49
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
49